MiniMed Likely to Ride on Pipeline Growth, BofA Says

MT Newswires Live03-31

MiniMed (MMED) is a large-scale, fully-stacked diabetes company

sitting at an inflection point with pipeline to accelerate growth, BofA Securities said in a Tuesday report.

"We see the stock working on consistent execution," the note said, adding that the stock's valuation is not reflective of outer year growth or free cash flow.

MiniMed, a recent spinoff from Medtronic (MDT), offers insulin pumps and Continuous Glucose Monitor for insulin-intensive patients where the need for such technology is critical, it said.

The report said its scale has positive implications for margins and free cash flow. It also said revenue growth is forecast to accelerate to about 11% in fiscal 2030 from roughly 8% in 2026.

BofA started coverage with a buy rating and a $27 price target.

Price: 14.98, Change: +0.63, Percent Change: +4.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment